15 results about "Neuroregulator" patented technology

An example of a system may include a processor and a memory device comprising instructions, which when executed by the processor, cause the processor to: access a patient metric of a subject; use the patient metric as an input to a machine learning algorithm, the machine learning algorithm to search a plurality of neuromodulation parameter sets and to identify a candidate neuromodulation parameter set of the plurality of neuromodulation parameter sets, the candidate neuromodulation parameter set designed to produce a non-regular waveform that varies over a time domain and a space domain; and program a neuromodulator using the candidate neuromodulation parameter set to stimulate the subject.

A method for rehabilitating a patient with neurological deficit or neuromuscular disease, the method including providing a medical walker with an operably connected leg brace, wherein a swing linkage connects the leg brace to the medical walker proximate to a knee of a compromised limb of the patient. The method further includes sensing movement and position in space of the compromised limb of the patient via one or more sensors attached to the leg brace and generating limb data. The method also includes analyzing the limb data, and signaling one or more neuromodulators to activate based at least in part upon analysis of the limb data, wherein the signaling is timed to assist gait motion of the compromised limb.

The invention discloses a composition for improving immunity and delaying senescence and a preparation method thereof. Belongs to the technical field of functional health. The composition comprises the following components in parts by mass: 5-50 parts of collagen, 10-80 parts of paeonia ostii tea, 1-20 parts of an antioxidant, 3-10 parts of an intestinal microecology regulator and 1-3 parts of an energy metabolism and nerve regulator. According to the invention, through multi-system cooperation and multi-target intervention, dual effects of immune enhancement and senescence delay are realized. Through scientific compounding and a special process, the product has the advantages of stable components, uniform activity and good solubility. Animal experiments and theoretical models show that immune organs can be effectively protected, accumulation of aging markers is reduced, and a solution is provided for development of comprehensive anti-aging health products.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

Methods and systems for providing stimulation therapy are disclosed. Embodiments of the system include an implantable stimulator and an external controller configured to control the implantable stimulator. A clinician can prescribe a set amount of stimulation therapy to a patient. The external controller is programmed with the prescription. As the patient uses the external controller and the stimulator device the external controller tracks the amount of stimulation the patient uses. Once the patient has used all of the prescribed therapy the patient may return to the clinician for a follow-up appointment.

A device and method for marking a surface, such as skin, to show the location of anticipated diffusion for a neuromodulator, such as botox, before administration of the neuromodulator is provided. The device comprises flexible leaf members having distal end surfaces and a separate tip end which transfer corresponding marks to the surface. The visualized anticipated diffusion pattern that results allows for a safer and more predictable outcome when administering the neuromodulator.

The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

The present disclosure is directed to the neuromodulation of two or more neuronal targets in treatment of a medical condition. The neuronal targets can be sympathetic nerves, parasympathetic nerves or a combination of sympathetic and parasympathetic nerves. The neuromodulation of the neuronal targets can comprise stimulation of the neuronal target, a conduction block of the neuronal targets or a combination of stimulation and conduction blocks of the neuronal targets. The neuromodulation is performed by one or more neuroregulators which can comprise electrical or non-electrical neuroregulators. The neuromodulation of each of the neuronal targets can include the same or different start / end times, the same or different durations, and / or the same or different neuromodulation patterns. The neuromodulation of the first neuronal target works in cooperation with the neuromodulation of the second neuronal target to treat a medical condition.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

The present invention discloses a strain of Weissella confusa and its application in producing neuromodulators. The strain is called Weissella confusa W1h, and the deposit number is CGMCC NO.25725. The strain was deposited at the General Microbiology Center of China National Committee for the Preservation and Administration of Microorganisms at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing on September 15, 2022. Weissella confusa W1h in the present invention can secrete neuromodulators such as tryptophan, dopamine, short-chain fatty acids, etc., which can be used for the development and utilization of antidepressant probiotic products, and the strain has good tolerance to the gastrointestinal environment, has high intestinal adhesion and antibacterial activity, and can be used to improve the structure of intestinal microbial flora and inhibit the growth and reproduction of pathogenic bacteria.

The present disclosure relates to kappa opioid receptor ligands and pharmaceutical compositions thereof, and their utility as neurological modulators (e.g., antinociceptive agents, antidepressants, anxiolytic agents, antipruritic agents). Specifically, the disclosed kappa opioid ligands are G protein-biased kappa opioid agonists containing a core and three distinct arms, as shown in formula (A) below. TIFF2026507218000102.tif2335

Methods and systems for providing stimulation therapy are disclosed. Embodiments of the system include an implantable stimulator and an external controller configured to control the implantable stimulator. A clinician can prescribe a set amount of stimulation therapy to a patient. The external controller is programmed with the prescription. As the patient uses the external controller and the stimulator device the external controller tracks the amount of stimulation the patient uses. Once the patient has used all of the prescribed therapy the patient may return to the clinician for a follow-up appointment.

Medicaments and methods for preventing, treating, or delaying heart failure with preserved ejection fraction in mammals are provided. The present invention provides the use of neuregulin in the manufacture of a medicament for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, and a pharmaceutical preparation for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, the pharmaceutical preparation comprising an effective amount of neuregulin.

This invention belongs to the field of deuterated labeled compound synthesis technology, and discloses a method for deuterating indole compounds and its application. The deuteration method of this invention includes the following steps: mixing an indole compound, a transition metal catalyst, a complex ligand, an additive, and a deuteration solvent, reacting to obtain a deuterated product; the complex ligand includes a first ligand and a second ligand; the first ligand includes a lactam compound; the second ligand includes a pyridone compound; and the deuteration solvent includes deuterated acetic acid. The deuteration method of this invention achieves highly selective hydrogen-deuterium exchange at multiple sites on the indole ring of indole compounds (especially the difficult-to-modify C4-C7 sites) through the synergistic effect of the catalyst, the dual ligand, and the deuteration solvent system. Furthermore, it can be applied to the deuteration synthesis of drugs such as the anti-inflammatory drug indomethacin, the cancer adjuvant therapy drug tropisetron, and the neuromodulator melatonin, providing key technical support for the development of deuterated drugs.